1. Medtech Insight
  4. >>Clinical Trials

FDA Essure Actions Draw Lawmaker Ire, Demand For Product Withdrawal

While FDA has gone beyond an advisory committee recommendation to require a registry to monitor Bayer's Essure permanent contraception device, lawmakers say the agency's call for a new postmarket study and black box labeling requirements spelled out in a draft guidance are insufficient to address serious concerns with safety.

FDA is taking two separate actions in response to concerns about adverse reactions to Bayer AG's Essure permanent infertility implant. However, at least two lawmakers critical of the implant are continuing calls to remove the product from the market.

On Feb. 29, FDA announced its actions after months of review of thousands of adverse events recorded from women who have used Essure and following an advisory panel meeting last fall

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D